Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (96)

III-01Oliver Ackaert

Building a reproducible pharmacometrics environment to ensure quality, continuity, efficiency, and good communication

Thursday 10:15-11:45

III-02Linda Aulin

Tapping into the potential of pharmacometrics in preclinical infection models: a low-hanging fruit or joined efforts needed?

Thursday 10:15-11:45

III-03Emily Behrens

Influence of interoccasion variability on parameter estimates of a population pharmacokinetic model under various sparse study designs

Thursday 10:15-11:45

III-04Brigitta Bodak

Facilitating structural population PK model building for pharmacometricians and beyond

Thursday 10:15-11:45

III-05Fan Cheng

Favipiravir pharmacokinetics in immunocompromised infants and children with chronic RNA viral infections

Thursday 10:15-11:45

III-06S. Y. Amy Cheung

Predicting RSV prophylaxis in the infant target population – assessing monoclonal antibody versus maternal vaccination efficacy using MBMA

Thursday 10:15-11:45

III-07Marc Codaccioni

Predictive performance of two hepatic CYP3A4 ontogeny within a paediatric PBPK model.

Thursday 10:15-11:45

III-08Alessandro Di Deo

A model-based algorithm for mycophenolate dose adjustment in paediatric transplantation patients

Thursday 10:15-11:45

III-09Lucia Diaz Garcia

Individualized tacrolimus dosing in pediatric kidney transplantation: development of PBPK-based predictive models, simulations and applications (ModSimTer-Tacro Study)

Thursday 10:15-11:45

III-10Summer Feng

Exposure-safety Markov modeling of ocular adverse events in patient populations treated with tisotumab vedotin

Thursday 10:15-11:45

III-11Klervi GOLHEN

Characterizing effect of methotrexate on adalimumab PK in pediatric patients with inflammatory rheumatic disease

Thursday 10:15-11:45

III-12Silvia Grandoni

Efficacy extrapolation and dose rationale for duloxetine in paediatric chronic pain

Thursday 10:15-11:45

III-13Yuchen Guo

Generation of realistic virtual adult populations using the NHANES database: a copula approach

Thursday 10:15-11:45

III-14Niklas Hartung

An information-theoretic evaluation of vine copula models for high-dimensional covariate distributions

Thursday 10:15-11:45

III-15Matthieu Jacobs

Accounting for uncertainty in the application of generic PBPK workflow to candidate selection

Thursday 10:15-11:45

III-16Christos Kaikousidis

In Silico Dosimetry Study of Tc99m-Tetrofosmin in Children Using a Novel PBPK Model in Humans Built from SPECT Imaging Data

Thursday 10:15-11:45

III-17Daniel Kaschek

How to reduce the total number of samples in a bioequivalence study without impacting statistical power

Thursday 10:15-11:45

III-18Csaba Katai

An asymptotic description of a basic FcRn-regulated clearance mechanism and its implications for PBPK modelling of large antibodies

Thursday 10:15-11:45

III-19Takayuki Katsube

Global Sensitivity Analysis for Effects of Correlated Covariates Using Shapley Value

Thursday 10:15-11:45

III-20Lina Keutzer

Model-based experimental design recommendations for in vivo studies of the novel anti-tuberculosis drug MPL-447 improve characterization of PK and PD

Thursday 10:15-11:45

III-21Feras Khalil

A joint parent-metabolite model to characterize the pharmacokinetic profile of tapentadol and its metabolites in the pediatric population and inform a model-based evaluation of a post-approval commitment pediatric trial

Thursday 10:15-11:45

III-22Christina Kovar

Physiologically Based Pharmacokinetic Modeling of Dasatinib to Describe Enzyme-Mediated and pH-Dependent Drug–Drug Interaction Scenarios

Thursday 10:15-11:45

III-23

Model-informed development of Mim8 – a novel bispecific antibody for the treatment of haemophilia A

Thursday 10:15-11:45

III-24Katharina Krollik

Oral absorption modeling of weakly basic drugs – Combining in vitro and in silico models

Thursday 10:15-11:45

III-25Marie Lambert

Population pharmacokinetic model to assess bone marrow absorbed dose after 177Lu-Dotatate administration

Thursday 10:15-11:45

III-26Paul Lang

Leveraging Open Systems Biology Standards for Improved Reusability and Reproducibility of Pharmacological Models

Thursday 10:15-11:45

III-27Julia Larsson

PK and PBPK modeling approaches to describe the lung and systemic exposure after inhalation of AZD4604

Thursday 10:15-11:45

III-28Félicien Le Louedec

Model-informed precision dosing of high-dose IV busulfan in Thai pediatric patients

Thursday 10:15-11:45

III-29Félicien Le Louedec

Model-informed precision dosing of protein kinase inhibitors: benefits and limits. The example of imatinib.

Thursday 10:15-11:45

III-30Maxime Le Merdy

Ocular Exposure Extrapolation Across Multiple Species Using PBPK Modeling and Simulation: Latanoprost Solution Case Study

Thursday 10:15-11:45

III-31Donghwan Lee

A comparative population pharmacokinetic analysis of nafamostat mesilate in patients receiving extracorporeal membrane oxygenation therapy (ECMO) support: central venous samples vs. ECMO circuit samples

Thursday 10:15-11:45

III-32Apolline Lefevre

A mechanistic PK/PD model to predict cytokine release and tumor cell killing associated to T-cell bispecific therapies

Thursday 10:15-11:45

III-33Romain Leroux

Design evaluation and optimisation in nonlinear mixed effects models with the R package PFIM 6.0

Thursday 10:15-11:45

III-34Xia Li

Model Informed Dose Evaluation for Aticaprant in Adolescent Patients Following the Adult Dose Regimen

Thursday 10:15-11:45

III-35Andreas Lindauer

e-Campsis: a Shiny PK/PD model simulator based on Campsis

Thursday 10:15-11:45

III-36Cong Liu

Application of translational physiologically based pharmacokinetic (PBPK) model for elucidating the complex disposition of ADCs: a case study with T-DM1

Thursday 10:15-11:45

III-37Feiyan Liu

Unravelling the effects of acute inflammation on pharmacokinetics: a model-based analysis focusing on renal excretion and CYP3A4-mediated metabolism

Thursday 10:15-11:45

III-38Han Liu

Informing the selection of clinically relevant pharmacokinetic target range for Therapeutic Drug Monitoring (TDM) of sunitinib: a pharmacometric simulation framework

Thursday 10:15-11:45

III-39Sarah Lobet

Influence of body composition on the pharmacokinetics of monoclonal antibodies : example of cetuximab and bevacizumab

Thursday 10:15-11:45

III-40Helena Loer

Physiologically Based Pharmacokinetic Modeling of Imatinib and Its Main Metabolite for Drug–Drug Interaction Predictions

Thursday 10:15-11:45

III-41Aurelie Lombard

Exploring the use of constant and time-varying observation-based versus model-based tumour size metrics for early predictions of drug efficacy on overall survival in malignant pleural mesothelioma

Thursday 10:15-11:45

III-42Orphélie Lootens

Building a physiologically-based pharmacokinetic model for a carcinogenic food contaminant aflatoxin B1

Thursday 10:15-11:45

III-43Vincent Madelain

Impact of interaction model choice in PKPD analysis evaluating drug combination in TGI in vivo studies

Thursday 10:15-11:45

III-44Claude Magnard

Pharmacokinetic Modeling of Fentanyl Citrate and Norfentanyl in Calves Using a Nonlinear Mixed-Effects Approach

Thursday 10:15-11:45

III-45John Maringwa

Partial residual plots (PRPs) as an integrated model diagnostic tool in model-based meta-analysis (MBMA)

Thursday 10:15-11:45

III-46Srinivas Martha

A meta-analysis of prevalence and incidence of diabetic peripheral neuropathy in Asia

Thursday 10:15-11:45

III-47Frederico Martins

Establishment of Virtual Bioequivalence via DoE-PBPM Model: A Donepezil Case Study

Thursday 10:15-11:45

III-48Luca Marzano

Explainable machine learning for time-to-event analysis: exploring time-dependent covariate effects on models of small cell lung cancer

Thursday 10:15-11:45

III-49Emir Mesic

Population pharmacokinetics of Jesduvroq (daprodustat) in chronic kidney disease patients with anemia

Thursday 10:15-11:45

III-50Frano Mihaljevic

Automatized reporting in the applications of MonolixSuite

Thursday 10:15-11:45

III-51Samer Mouksassi

The African applied pharmacometrics training fellowship: 1 year later

Thursday 10:15-11:45

III-52Mourad Mseddi

Population pharmacokinetics of abiraterone in patients with metastatic castration resistant prostate cancer

Thursday 10:15-11:45

III-53Ida Neldemo

Application of tumor size modelling and simulations to support the dose selection of BI 907828 for a Phase II study

Thursday 10:15-11:45

III-54Thi Lien Ngo

Development of a Physiological-Based Pharmacokinetic Model for Ritonavir: Unraveling its Triphasic Effects as CYP3A Inhibitor, CYP3A Inducer, and Pgp Inhibitor.

Thursday 10:15-11:45

III-55Ana Novakovic

Empirical Power Evaluations of an Item Response Model in Parkinson’s Disease Patients

Thursday 10:15-11:45

III-56Frances Okibedi

Investigating Alternative Daily Dose Regimens for Bedaquiline in Treatment of Multidrug-Resistant Tuberculosis using an Interactive Shiny Application

Thursday 10:15-11:45

III-57Jessica Ou

Development of a physiologically-based pharmacokinetic model to understand and predict the disposition of gallium-68 radiolabeled-dendrimers in vivo

Thursday 10:15-11:45

III-58Theodoros Papathanasiou

Population pharmacokinetics of belantamab mafodotin in relapsed or refractory multiple myeloma patients with severe renal impairment

Thursday 10:15-11:45

III-59Sara Peribanez

A physiologically-based pharmacokinetic model for V937, a novel oncolytic virus, in mice

Thursday 10:15-11:45

III-60Antoine Pitoy

Contribution of modelling jointly progression-free survival and biomarker longitudinal data for therapeutic evaluation in oncology

Thursday 10:15-11:45

III-61Luna Prieto Garcia

An Integrated PBPK-Quantitative Systems Pharmacology Model for Statins to Assess the Variability and Implications of Transporter-Mediated Distribution

Thursday 10:15-11:45

III-62Alicja Puszkiel

Nivolumab de-escalation in patients with complete response: model-based simulations of alternative dosing regimens and noninferiority clinical trials

Thursday 10:15-11:45

III-63Federico Reali

A minimal PBPK mice model to support the preclinical development of drugs against tuberculosis.

Thursday 10:15-11:45

III-64Javier Reig-López

Chirality matters: physiologically based pharmacokinetic modelling of ibuprofen enantiomers

Thursday 10:15-11:45

III-65Pascale Rietveld

Population pharmacokinetics of intraperitoneal irinotecan and SN-38 in patients with peritoneal metastases from colorectal origin

Thursday 10:15-11:45

III-66Maša Roganović

Modelling fatigue events in prostate cancer patients on radiotherapy

Thursday 10:15-11:45

III-67Davide Ronchi

Model-based analysis of patient-derived organoids for evaluating anticancer drugs

Thursday 10:15-11:45

III-68Alberto Russu

Population pharmacokinetic modeling and bioequivalence clinical trial simulations of niraparib plus abiraterone acetate administered as single-agent combination and dual-acting tablets plus prednisone for the treatment of metastatic castration-resistant prostate cancer

Thursday 10:15-11:45

III-69Anuraag Saini

Development of mPBPK model to support translation decision-making for novel bispecific therapeutics

Thursday 10:15-11:45

III-70Ayatallah Saleh

Unravelling the complex inhibition network of voriconazole and its metabolites using a middle-out PBPK approach

Thursday 10:15-11:45

III-71Javier Sanchez Fernandez

Building evidence on the PKPD relationship with bispecific co-stimulatory antibodies using in vitro data: FAP-4-1BBL example

Thursday 10:15-11:45

III-72Aymara Sancho

Mechanistic characterization of oscillatory patterns in unperturbed tumor growth dynamics: the interplay between cancer cells and components of the tumor microenvironment.

Thursday 10:15-11:45

III-73Keshava Sannala

Comparison of Pumas and NONMEM in parameter estimation of a complex pharmacodynamic model

Thursday 10:15-11:45

III-74Darlene Santiago

A Pharmacometric approach for opioid use disorder in Puerto Rico: A research agenda to individualize buprenorphine pharmacotherapy.

Thursday 10:15-11:45

III-75Emilie Schindler

Population PK-PD modeling and exposure-response analysis in multiple myeloma patients treated with intravenous forimtamig, a T-cell engaging 2:1 bispecific antibody targeting GPRC5D and CD3

Thursday 10:15-11:45

III-76Miriam Schirru

A QSP model for predicting efficacy assessment of combined treatment of radiotherapy and anti-PD-1 for NSCLC patients through virtual clinical trials.

Thursday 10:15-11:45

III-77Alejandro Serrano Alcaide

Application of an immune-oncology framework to explore the role of regulatory T cells in antitumor response.

Thursday 10:15-11:45

III-78Raman Sharma

A meta-analysis for predicting early bactericidal activity of beta-lactam antibiotics against pulmonary tuberculosis

Thursday 10:15-11:45

III-79Hinke Huisman-Siebinga

Optimizing radionuclide therapy with 177Lu-HA-DOTATATE in patients with neuroendocrine tumors using semi-physiological population PK models

Thursday 10:15-11:45

III-80Hanna Silber Baumann

Dose confirmation based on population pharmacokinetics within LUMINESCE (NCT04963270); a Phase III, randomized, double-blind, placebo-controlled study evaluating satralizumab in patients with generalized myasthenia gravis

Thursday 10:15-11:45

III-81Erik Sjögren

Mechanistic modelling of bioavailability and local immunogenicity after subcutaneous administration within the Open Systems Pharmacology framework

Thursday 10:15-11:45

III-82Tomas Sou

Population PK/PD modelling of platelet dynamics for dose selection in patients with haematological malignancies

Thursday 10:15-11:45

III-83Viktoria Stachanow

Drug and target parameters impacting target profiles for mono- and multi-specific NANOBODY® molecules – a model-based sensitivity analysis

Thursday 10:15-11:45

III-84Herbert Struemper

Development of a joint tumor size (TS)–overall survival (OS) modelling and simulation (M&S) framework supporting oncology development decision making

Thursday 10:15-11:45

III-85Huybrecht T'jollyn

Individual virtual controls as surrogate for a control arm – application for siRNA and NA therapy in chronic hepatitis B infection

Thursday 10:15-11:45

III-86Zhiyuan Tan

Population pharmacokinetic analysis of pazopanib in adult patients with metastatic renal cell carcinoma and soft tissue sarcoma

Thursday 10:15-11:45

III-87David Ternant

A multi drug disposition model accounting for rituximab antigen binding portion (Fab) and crystallizable (Fc) mediated drug disposition mechanisms

Thursday 10:15-11:45

III-88Paul Thoueille

Pharmacometrics-based analysis of long-acting cabotegravir over 6 months in real-life people living with HIV in Switzerland

Thursday 10:15-11:45

III-89Pauline Traynard

Bayesian individual dynamic predictions via a convenient R function using MonolixSuite

Thursday 10:15-11:45

III-90Cristian Valiante

PBPK model-based extrapolation from adults to children to predict furosemide oral solution bioavailability

Thursday 10:15-11:45

III-91Anne van Rongen

Quantification of renal drug clearance in neonates born Small for Gestational Age (SGA) compared to neonates born Appropriate for Gestational Age (AGA)

Thursday 10:15-11:45

III-92Sergei Vavilov

R framework for reproducible and quality-controlled modeling and simulation with the Open Systems Pharmacology Software

Thursday 10:15-11:45

III-93Yunjiao Wu

When will the glomerular filtration rate in preterm neonates catch up to their term peers?

Thursday 10:15-11:45

III-94Tan Zhang

Exploring the impact of obesity on drug clearance using PBPK modelling approaches: influential variables affecting scaling from non-obese to obese subjects for drugs metabolized in the liver

Thursday 10:15-11:45

III-95Han Zheng

MaS: population pharmacometric modeling in Python

Thursday 10:15-11:45

III-96Yuanxi Zou

Evaluating two strategies for the design of pediatric pharmacokinetic studies

Thursday 10:15-11:45